CO5090836A1 - 3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcio - Google Patents
3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcioInfo
- Publication number
- CO5090836A1 CO5090836A1 CO99044882A CO99044882A CO5090836A1 CO 5090836 A1 CO5090836 A1 CO 5090836A1 CO 99044882 A CO99044882 A CO 99044882A CO 99044882 A CO99044882 A CO 99044882A CO 5090836 A1 CO5090836 A1 CO 5090836A1
- Authority
- CO
- Colombia
- Prior art keywords
- compound
- formula
- fosfonooxi
- aminofenil
- isobutil
- Prior art date
Links
- IVKWOTXJDJIJKY-UHFFFAOYSA-N [Ca].C(N)(OCCC)=O Chemical compound [Ca].C(N)(OCCC)=O IVKWOTXJDJIJKY-UHFFFAOYSA-N 0.000 title 1
- JFSPBVWPKOEZCB-UHFFFAOYSA-N fenfuram Chemical compound O1C=CC(C(=O)NC=2C=CC=CC=2)=C1C JFSPBVWPKOEZCB-UHFFFAOYSA-N 0.000 title 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical group ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 abstract 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 229910001424 calcium ion Inorganic materials 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000000865 phosphorylative effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El compuesto de fórmula (I)<EMI FILE="99044882_1" ID="1" IMF=JPEG >Una composición farmacéutica que está caracterizada porque comprende un compuesto como el reivindicado en la reivindicación 1 junto con al menos un diluyente farmacéuticamente aceptable ó vehículo de éste.Un proceso para la preparación de un compuesto de formula (I)<EMI FILE="99044882_2" ID="2" IMF=JPEG >Que comprende la reducción de un compuesto de fórmula (IV)<EMI FILE="99044882_3" ID="3" IMF=JPEG >En la presencia de un agente reductor adecuado en un solvente adecuado, seguida por adición de agua y una fuente de iones calcio.Un proceso para la preparación de un compuesto de fórmula (I) como la reivindicada en la reivindicación 7, que está caracterizada porque el agente de fosforilación es oxicloruro de fósforo.1Un proceso para la preparación de un compuesto de fórmula (I) como el reivindicado en la reivindicación 7 ó 10, que está caracterizado porque el agente fosforilante es añadido en la presencia de una base.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9815567.4A GB9815567D0 (en) | 1998-07-18 | 1998-07-18 | Antiviral compound |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5090836A1 true CO5090836A1 (es) | 2001-10-30 |
Family
ID=10835689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO99044882A CO5090836A1 (es) | 1998-07-18 | 1999-07-15 | 3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcio |
Country Status (48)
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
NZ518580A (en) * | 1999-10-06 | 2004-01-30 | Us Gov Health & Human Serv | Hexahydrofuro[2,3-B]furan-3-YL-N- {3-[1,3-benzodioxol-5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor |
CA2387016C (en) * | 1999-10-08 | 2010-09-28 | William H. Miller | Acrylamide derivatives as fab i inhibitors |
WO2003088897A2 (en) * | 2001-04-06 | 2003-10-30 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
TWI332956B (en) * | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
EP1575951B1 (en) * | 2002-12-06 | 2014-06-25 | Debiopharm International SA | Heterocyclic compounds, methods of making them and their use in therapy |
WO2004082586A2 (en) | 2003-03-17 | 2004-09-30 | Affinium Pharmaceuticals, Inc. | Phamaceutical compositions comprising inhibitors of fab i and further antibiotics |
ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
MXPA05011296A (es) | 2003-04-25 | 2006-01-24 | Gilead Sciences Inc | Conjugados de fosfonato inhibidores de la cinasa. |
US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
WO2005030194A1 (en) * | 2003-09-30 | 2005-04-07 | Tibotec Pharmaceuticals Ltd. | Hcv inhibitiing sulfonamides |
WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
JP2007508843A (ja) | 2003-10-24 | 2007-04-12 | ギリアード サイエンシーズ, インコーポレイテッド | 治療用化合物の同定のための方法および組成物 |
WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
US20080287471A1 (en) | 2003-12-22 | 2008-11-20 | Maria Fardis | 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity |
PL1828167T3 (pl) * | 2004-06-04 | 2015-02-27 | Debiopharm Int Sa | Pochodne akryloamidu jako środki antybiotykowe |
ES2720618T3 (es) | 2004-07-27 | 2019-07-23 | Gilead Sciences Inc | Análogos de fosfonato de compuestos de inhibidores de VIH |
EP2319581B1 (en) | 2004-11-26 | 2015-02-25 | UCL Business PLC | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
WO2007067416A2 (en) * | 2005-12-05 | 2007-06-14 | Affinium Pharmaceuticals, Inc. | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
EP2054422B1 (en) | 2006-07-20 | 2017-06-14 | Debiopharm International SA | Acrylamide derivatives as fab i inhibitors |
EP3255045A1 (en) * | 2007-02-16 | 2017-12-13 | Debiopharm International SA | Salts, prodrugs and polymorphs of fab i inhibitors |
JP5448854B2 (ja) | 2007-03-12 | 2014-03-19 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー−プロテアーゼ阻害剤複合体 |
US9095620B2 (en) * | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
UA103329C2 (ru) | 2008-07-08 | 2013-10-10 | Гилиад Сайенсиз, Инк. | Соли соединений-ингибиторов вич |
NZ595706A (en) | 2009-04-03 | 2014-01-31 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
EP2432788A1 (en) * | 2009-05-20 | 2012-03-28 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
EA025735B1 (ru) | 2009-06-08 | 2017-01-30 | ЮСиЭл БИЗНЕС ПиЭлСи | Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата |
US20120108501A1 (en) | 2009-06-12 | 2012-05-03 | Nektar Therapeutics | Protease Inhibitors |
US20120208787A1 (en) * | 2009-06-30 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline form of fosamprenavir calcium |
US9085592B2 (en) | 2009-09-16 | 2015-07-21 | Ranbaxy Laboratories Limited | Process for the preparation of fosamprenavir calcium |
US20110165202A1 (en) * | 2010-01-07 | 2011-07-07 | Pliva Hrvatska D.O.O. | Solid state forms of fosamprenavir calcium salt and processes for preparation thereof |
ES2688925T3 (es) | 2010-01-27 | 2018-11-07 | Viiv Healthcare Company | Tratamiento antiviral |
US20110224443A1 (en) * | 2010-03-15 | 2011-09-15 | Venkata Naga Brahmeshwara Rao Mandava | Preparation of fosamprenavir calcium |
WO2011114212A1 (en) | 2010-03-19 | 2011-09-22 | Lupin Limited | Ammonium, calcium and tris salts of fosamprenavir |
US20130211108A1 (en) * | 2010-06-18 | 2013-08-15 | Mylan Laboratories Ltd | Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts |
WO2012032389A2 (en) | 2010-09-10 | 2012-03-15 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
KR101888215B1 (ko) | 2010-10-06 | 2018-09-20 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제조 방법 |
CN102453054B (zh) * | 2010-10-29 | 2015-06-10 | 浙江九洲药业股份有限公司 | 一种福沙那韦衍生物的制备方法及相关中间体 |
CN102453053B (zh) * | 2010-10-29 | 2014-11-26 | 浙江九洲药业股份有限公司 | 一种福沙那韦钙晶体及其制备方法 |
WO2012085625A1 (en) | 2010-12-21 | 2012-06-28 | Lupin Limited | Process for the preparation of fosamprenavir calcium and intermediate used in its preparation |
JP2014513044A (ja) * | 2011-02-10 | 2014-05-29 | マイラン ラボラトリーズ リミテッド | ホスアンプレナビルカルシウム結晶およびその調製方法 |
WO2013011485A1 (en) | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
WO2013105118A1 (en) | 2012-01-10 | 2013-07-18 | Council Of Scientific & Industrial Research | A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir |
JP6085026B2 (ja) | 2012-06-19 | 2017-02-22 | デビオファーム インターナショナル エスエーDebiopharm International Sa | (e)−n−メチル−n−((3−メチルベンゾフラン−2−イル)メチル)−3−(7−オキソ−5,6,7,8−テトラヒドロ−1,8−ナフチリジン−3−イル)アクリルアミドのプロドラッグ誘導体 |
JP6797117B2 (ja) | 2014-11-24 | 2020-12-09 | ユーシーエル ビジネス リミテッド | アンモニア降下療法を用いた肝星細胞活性化関連疾患の処置 |
US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
US10751351B2 (en) | 2016-02-26 | 2020-08-25 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
AU2018266357B2 (en) | 2017-05-11 | 2022-12-08 | Ocera Therapeutics, Inc. | Processes of making L-ornithine phenylacetate |
PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2698826A (en) * | 1951-02-13 | 1955-01-04 | Merco Centrifugal Co | Alcohol manufacturing process |
US3437267A (en) * | 1966-03-24 | 1969-04-08 | Alfa Laval Ab | Centrifuge |
JPH0244315B2 (ja) * | 1982-06-14 | 1990-10-03 | Microbial Chem Res Found | Supagarinn155hosufueetooyobisonoseizoho |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
PL341762A1 (en) * | 1997-12-24 | 2001-05-07 | Vertex Pharma | Precursors of aspartil protease inhibitors |
AU2010299A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
GB9812189D0 (en) * | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
WO2000018384A2 (en) * | 1998-09-28 | 2000-04-06 | Glaxo Group Limited | Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir |
AU762349B2 (en) * | 1998-11-04 | 2003-06-26 | Pharmacia & Upjohn Company | Method for improving the pharmacokinetics of tipranavir |
CZ20002364A3 (cs) * | 1998-12-23 | 2000-11-15 | Vertex Pharmaceuticals Incorporated | Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje |
GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
ATE377011T1 (de) * | 1999-11-24 | 2007-11-15 | Merck & Co Inc | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer |
-
1998
- 1998-07-18 GB GBGB9815567.4A patent/GB9815567D0/en not_active Ceased
-
1999
- 1999-07-14 DZ DZ990145A patent/DZ2845A1/xx active
- 1999-07-14 GC GCP1999203 patent/GC0000105A/xx active
- 1999-07-14 AR ARP990103446A patent/AR019388A1/es not_active Application Discontinuation
- 1999-07-15 GE GEAP19995716A patent/GEP20033030B/en unknown
- 1999-07-15 AU AU50379/99A patent/AU766056B2/en not_active Expired
- 1999-07-15 JO JO19992114A patent/JO2114B1/en active
- 1999-07-15 PT PT99934698T patent/PT1098898E/pt unknown
- 1999-07-15 TR TR2001/00111T patent/TR200100111T2/xx unknown
- 1999-07-15 SV SV1999000096A patent/SV1999000096A/es not_active Application Discontinuation
- 1999-07-15 YU YU3401A patent/YU3401A/sh unknown
- 1999-07-15 SK SK76-2001A patent/SK285311B6/sk not_active IP Right Cessation
- 1999-07-15 DK DK99934698T patent/DK1098898T3/da active
- 1999-07-15 AT AT99934698T patent/ATE229964T1/de active
- 1999-07-15 PL PL99345620A patent/PL195736B1/pl unknown
- 1999-07-15 EA EA200100053A patent/EA003191B1/ru not_active IP Right Cessation
- 1999-07-15 US US09/744,051 patent/US6514953B1/en not_active Expired - Lifetime
- 1999-07-15 HU HU0103432A patent/HU229700B1/hu unknown
- 1999-07-15 CA CA2337857A patent/CA2337857C/en not_active Expired - Lifetime
- 1999-07-15 ID IDW20010145A patent/ID28070A/id unknown
- 1999-07-15 EP EP02013136A patent/EP1240903A3/en not_active Withdrawn
- 1999-07-15 MY MYPI99002983A patent/MY122323A/en unknown
- 1999-07-15 OA OA1200100016A patent/OA11706A/fr unknown
- 1999-07-15 CN CNB998108383A patent/CN1188422C/zh not_active Expired - Lifetime
- 1999-07-15 ES ES99934698T patent/ES2189450T3/es not_active Expired - Lifetime
- 1999-07-15 NZ NZ509291A patent/NZ509291A/en not_active IP Right Cessation
- 1999-07-15 TN TNTNSN99145A patent/TNSN99145A1/fr unknown
- 1999-07-15 EE EEP200100038A patent/EE200100038A/xx unknown
- 1999-07-15 CZ CZ20010219A patent/CZ300447B6/cs not_active IP Right Cessation
- 1999-07-15 GT GT199900111A patent/GT199900111A/es unknown
- 1999-07-15 EP EP99934698A patent/EP1098898B1/en not_active Expired - Lifetime
- 1999-07-15 MA MA25684A patent/MA26660A1/fr unknown
- 1999-07-15 KR KR1020017000740A patent/KR100694721B1/ko not_active IP Right Cessation
- 1999-07-15 WO PCT/EP1999/004991 patent/WO2000004033A1/en active IP Right Grant
- 1999-07-15 IL IL14082499A patent/IL140824A/en not_active IP Right Cessation
- 1999-07-15 BR BRPI9912156A patent/BRPI9912156B8/pt not_active IP Right Cessation
- 1999-07-15 CO CO99044882A patent/CO5090836A1/es unknown
- 1999-07-15 AP APAP/P/2001/002039A patent/AP2001002039A0/en unknown
- 1999-07-15 PE PE1999000714A patent/PE20000869A1/es not_active Application Discontinuation
- 1999-07-15 JP JP2000560139A patent/JP3437553B2/ja not_active Expired - Lifetime
- 1999-07-15 DE DE69904600T patent/DE69904600T2/de not_active Expired - Lifetime
- 1999-07-16 PA PA19998477801A patent/PA8477801A1/es unknown
- 1999-08-06 TW TW088113428A patent/TWI245770B/zh not_active IP Right Cessation
-
2001
- 2001-01-12 IS IS5808A patent/IS5808A/is unknown
- 2001-01-15 ZA ZA200100417A patent/ZA200100417B/en unknown
- 2001-01-17 HR HR20010046A patent/HRP20010046A2/hr not_active Application Discontinuation
- 2001-01-17 NO NO20010282A patent/NO329676B1/no not_active IP Right Cessation
- 2001-02-14 BG BG105253A patent/BG105253A/xx unknown
- 2001-07-13 HK HK01104903A patent/HK1034261A1/xx not_active IP Right Cessation
-
2002
- 2002-11-25 US US10/303,366 patent/US20030096795A1/en not_active Abandoned
- 2002-11-25 US US10/303,213 patent/US20030100537A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5090836A1 (es) | 3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcio | |
DE60019693D1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
BR0313197A (pt) | Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico | |
BR9908537A (pt) | Copolìmeros biocompatìveis e utilização dos mesmos | |
BR0111016A (pt) | Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos | |
CY1105399T1 (el) | Μεθοδος επιλεκτικης υποκαταστασεως των ταξανων | |
BR0103844A (pt) | Sistema de aditivo polimérico múltiplo, processo para produzir o mesmo, composição polimérica, e, processo para produzir a mesma | |
PT991653E (pt) | Novos compostos | |
GT199800197A (es) | Proceso para la sintesis de 1,3-dioles. | |
BR0207871A (pt) | Composição para liberar bisfosfonato para um alvo | |
PT1318791E (pt) | Composicao farmaceutica semi-solida de isotretinoina | |
BR0111126A (pt) | Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos | |
BR0210464A (pt) | Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto | |
BR0208017A (pt) | Combinação compreendendo combretastatina e agentes anticâncer | |
EA200500300A1 (ru) | Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение | |
BR0112337A (pt) | Derivados de fosfolipìdeos de ácido valpróico e suas misturas | |
ATE450254T1 (de) | Schwimmende pharmazeutische zusammensetzung mit einer aktiven phase und einer inaktiven phase | |
ES2187184T3 (es) | Fosfoepoxidos, procedimiento de fabricacion y aplicaciones. | |
CO5150166A1 (es) | (s)-10, 11-dihidro-3[2-(5,6,7,8-tetrahidro-1,8-naftiridin -2-il)-etoxi]-5h-dibenzo [a,d] cicloheptano-10-acido acetico | |
BR0308601A (pt) | inibidores de carboxipeptidase b de plasma | |
BR9914834A (pt) | Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese | |
BRPI9916820B8 (pt) | composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método | |
BR9906950A (pt) | Processo para a preparação de isoflavonas | |
AP2000001937A0 (en) | Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway. | |
BR9812875A (pt) | Processos para o tratamento de artrite reumatóide em um mamìfero, e para a fabricação de uma composição terapêutica para o tratamento de artrite reumatóide em um mamìfero, uso de um composto, e, composição farmacêutica |